TFEB mediates immune evasion and resistance to mTOR inhibition of renal cell carcinoma via induction of PD-L1.

CONCLUSIONS: These data revealed that TFEB mediates resistance to mTOR inhibition via induction of PD-L1 in human primary RCC tumors, RCC cells and murine xenograft model. Our data provide a strong rationale to target mTOR and PD-L1 jointly as a novel immunotherapeutic approach for RCC treatment.
PMID: 31383732 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - August 4, 2019 Category: Cancer & Oncology Authors: Zhang C, Duan Y, Xia M, Dong Y, Chen Y, Zheng L, Chai S, Zhang Q, Wei Z, Liu N, Wang J, Sun C, Tang Z, Cheng X, Wu J, Wang G, Zheng F, Laurence A, Li B, Yang XP Tags: Clin Cancer Res Source Type: research